MAPT and Alzheimer disease: To test whether other acetylcholinesterase inhibitors can modulate tau phosphorylation in a mouse model of AD, 5xFAD mice were orally injected with rivastigmine (2 mg/kg, p.o.)or vehicle daily for 2 weeks.